Efficacy and safety of vildagliptin and metformin combination therapy in type 2 diabetes
10.3760/cma.j.issn.1000-6699.2011.12.020
- VernacularTitle:维格列汀和二甲双胍联合治疗2型糖尿病的疗效与安全性
- Author:
Xianan ZHENG
;
Hong LI
- Publication Type:Journal Article
- Keywords:
Dipeptidyl peptidase-4 inhibitor;
Glucagon-like peptide-1;
Vildagliptin;
Diabetes mellitus;
type 2
- From:
Chinese Journal of Endocrinology and Metabolism
2011;27(12):后插1-后插4
- CountryChina
- Language:Chinese
-
Abstract:
Vildagliptin,a dipeptidyl peptidase-4 (DPP-4) inhibitor,is always used in combination with metformin.Data from multiple clinical trials showed that vildagliptin and metformin combination therapy can improve HbA1c,fasting blood glucose,and postprandial blood glucose without weight gain,good gastrointestinal (GI)tolerance,and no increase in the incidence of hypoglycemia.Vildagliptin increases plasma levels of glucagon-like peptide-1 ( GLP-1 ).When glucose levels are above normal fasting levels,enhanced GLP-1 levels stimulate insulin secretion.Mefformin has been shown to increase insulin sensitivity and inhibit hepatic glucose production.The effect of vildagliptin to increase plasma levels of intact GLP-1 was enhanced in patients receiving concomitant metformin.
